Health Trials

About this trial

COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.

Eligibility criteria

Qualifiers

To have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial Fibrillation, severe valvular disease)

Adults aged >35 years at the time of inclusion in the study,

With signed informed consent for their participation in the study.

Disqualifiers

Without at least one cardiovascular comorbidity,

With history of lung cancer

With any other active malignancy and undergoing treatment (chemotherapy/radiotherapy/immunotherapy)

With any thoracic or abdominal surgery planned during study follow-up period

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

900 Participants
are grouped into 1 trial group

Locations

2
Department of Respiratory Medicine, Medical School, Democritus University of Thrace, University General Hospital Alexandroupoli Greece
5th Pulmonary Department, "Sotiria" Chest Diseases Hospital, Athens, Greece Athens Greece

Sponsors and collaborators

Hellenic Thoracic Society

Lead sponsor

Source ClinicalTrials.gov